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The impact of donor lymphocyte infusion (DLI) initial cell dose on its outcome is known in patients with
chronic myeloid leukemia but limited in patients with other hematological malignancies. In this retrospective
study, we evaluated the effect of initial DLI CD3þ cell dose on graft-versus-host disease (GVHD) and overall
survival after DLI given for relapse of any hematological malignancies after allogeneic hematopoietic cell
transplantation (HCT) with high- or reduced-intensity conditioning. The cohort included 225 patients. Initial
DLI CD3þ cell dose per kilogram of recipient body weight was 1  107 (n ¼ 84; group A), >1.0 to <10  107
(n ¼ 58; group B), and 10  107 (n ¼ 66; group C). The initial cell dose was unknown for the remaining 17
patients. Cumulative incidence rates of GVHD at 12 months after DLI were 21%, 45%, and 55% for groups A, B,
and C, respectively. Multivariate analysis showed that initial DLI CD3þ cell 10  107 dose per kilogram is
associated with an increased risk of GVHD after DLI (P ¼ .03). Moreover, an initial DLI CD3þ cell dose of 10 
107 or higher did not decrease the risk of relapse and did not improve overall survival. Thus, these results
support the use of less than 10  107 CD3þ cell per kilogram as the initial cell dose of DLI for treatment of
persistent or recurrent hematological malignancy after HCT.
 2013 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.INTRODUCTION impact of initial cell dose on outcomes after DLI for other
Allogeneic hematopoietic cell transplantation (HCT) has
the potential to provide long-term survival and even cure in
patients with hematological malignancies [1,2]. Nonetheless,
relapse of malignancy after HCT remains a major cause of
transplantation failure. Donor lymphocyte infusion (DLI) is
one approach frequently used to treat patients with relapse
of hematologic malignancy after allogeneic HCT. The DLI
effect is mediated through the immunologic antitumor
activity of donor T cells and possibly natural killer cells [3-6].
Since the ﬁrst report of DLI in patients with relapsed chronic
myeloid leukemia (CML) after allogeneic HCT by Kolb et al. in
1990 [6], DLI has become a common approach to treat not
only CML but also acute leukemia, lymphoma, myelodys-
plastic syndrome (MDS), and multiple myeloma (MM) that
have relapsed after allogeneic HCT [7-13]. The beneﬁcial
graft-versus-leukemia effect of DLI may be offset by
morbidity and mortality related to graft-versus-host disease
(GVHD). Although a low initial cell dose followed by escala-
tion of doses of DLI canminimize the risk of GVHD in patients
treated for relapsed CML [14-16], the data regarding thedgments on page 956.
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13.03.001relapsed hematological malignancies are limited. The
primary objective of the current study was to determine the
effect of the initial DLI CD3þ T cell dose on subsequent GVHD
requiring systemic treatment and on overall survival (OS)
after DLI.
PATIENTS AND METHODS
The study cohort included 225 patients treated with DLI for relapsed
hematological malignancies after allogeneic HCT from November 1993
through October 2011. Patients received high- or reduced-intensity condi-
tioning regimens before HCT according to standard treatment plan or
prospective clinical trials and were treated at the Fred Hutchinson Cancer
Research Center (n ¼ 212) and at 3 participant institutions in the Seattle
Nonmyeloablative HCT Consortium: the University of Torino (n ¼ 9), the
Puget Sound VA Health Care System (n ¼ 2), and the Medical College of
Wisconsin (n ¼ 2). Follow-up was complete through July 2012. All patients
provided informed consent for treatment according to transplantation
protocols approved by each institutional review board. In addition, separate
institutional approval was obtained to gather data from patient records and
databases retrospectively.
DLI
All 225 patients in this study received DLI for treatment of relapsed
hematological malignancies after HCT. No prophylactic DLI treatment was
given. One hundred ﬁfty-four patients were treated with DLI in prospective
clinical trials, and 71 patients received DLI as a treatment plan. Patients with
rapidly progressive malignancies (ie, acute myeloid or lymphoid leukemia,
CML in blast phase, high-grade MDS, intermediate-high grade non-Hodgkin
lymphoma, Hodgkin lymphoma, or aggressive multiple myeloma) received
chemotherapy or radiation before DLI according to speciﬁc protocols or atTransplantation. Published by Elsevier Inc. All rights reserved.
Table 1
Patient Characteristics
Characteristic CD3þ Cell Dose, per Kilogram
Unknown
(n ¼ 17)
Group A
107 (n ¼ 84)
Group B
>107 to <108 (n ¼ 58)
Group C
108 (n ¼ 66)
P Value*
Patient age at DLI .14
0-29 yr 4 12 (14) 13 (22) 9 (14)
30-44 yr 7 25 (30) 11 (19) 27 (41)
45-59 yr 5 29 (35) 25 (43) 22 (33)
60-74 yr 1 18 (21) 9 (16) 8 (12)
Donor-recipient gender (n ¼ 220) .17
Other 14 65 (82) 40 (69) 52 (79)
Female to male 3 14 (18) 18 (31) 14 (21)
Disease diagnosis/risk at time of DLI .36
CMLechronic phase 6 16 (19) 9 (16) 10 (15)
Low-risk lymphoid malignanciesy 0 20 (24) 6 (10) 10 (15)
High-risk myeloid malignanciesz 6 36 (43) 32 (55) 37 (56)
High-risk lymphoid malignanciesx 5 12 (14) 11 (19) 9 (14)
Disease status at time of DLI .05
Complete remission 2 14 (17) 19 (33) 20 (30)
Not in complete remission 15 70 (83) 39 (67) 46 (70)
Donor origin <.0001
Related 13 48 (57) 46 (79) 64 (97)
Unrelated 4 36 (43) 12 (21) 2 (3)
Donor-recipient HLA match .07
Matched 13 77 (92) 57 (98) 65 (98)
Mismatched 4 7 (8) 1 (2) 1 (2)
Graft stem cell source (n ¼ 201) .004
Bone marrow 12 31 (49) 21 (38) 45 (68)
Mobilized blood 5 32 (51) 34 (62) 21 (32)
Conditioning intensity <.0001
Myeloablative 16 47 (56) 41 (71) 63 (95)
Nonmyeloablative 1 37 (44) 17 (29) 3 (5)
Prior acute GVHD (n ¼ 218) .05
0-I 4 34 (44) 25 (43) 17 (26)
II-IV 13 43 (56) 33 (57) 49 (74)
Prior chronic GVHD .14
No 11 60 (71) 39 (67) 37 (56)
Yes 6 24 (29) 19 (33) 29 (44)
Time from HCT to DLI .50
>1 yr 11 51 (61) 31 (53) 42 (64)
1 yr 6 33 (39) 27 (47) 24 (36)
Cytoreduction before DLI (n ¼ 220) .02
No 6 37 (45) 18 (31) 15 (24)
Yes 11 45 (55) 40 (69) 48 (76)
Donor CD3 chimerism at time of DLI (n ¼ 91) .70
>95% 1 32 (70) 20 (71) 7 (58)
95% 4 14 (30) 8 (29) 5 (42)
Donor BM chimerism at time of DLI (n ¼ 114) .75
>95% 5 25 (54) 18 (60) 13 (50)
95% 7 21 (46) 12 (40) 13 (50)
Lymphocyte count at time of DLI (n ¼ 217) .01
103/mL 10 47 (61) 24 (42) 25 (38)
<103/mL 7 30 (39) 33 (58) 41 (62)
G-CSF mobilized product for DLI (n ¼ 128) .02
No 0 41 (84) 37 (79) 18 (56)
Yes 0 8 (16) 10 (21) 14 (44)
IL-2 after DLI .02
No 15 83 (99) 55 (95) 58 (88)
Yes 2 1 (1) 3 (5) 8 (12)
Year of DLI <.0001
1992-1996 6 5 (6) 8 (14) 23 (35)
1997-2001 6 26 (31) 14 (24) 33 (50)
2002-2006 2 30 (36) 27 (47) 10 (15)
2007-2011 3 23 (27) 9 (16) 0
DLI indicates donor lymphocyte infusion; CML, chronic myeloid leukemia; GVHD, grant-versus-host disease; HCT, hematopoietic cell transplantation; BM, bone
marrow; G-CSF, granulocyte-colony stimulating factor.
Data are presented as n (%) unless otherwise indicated.
* Among groups A, B, and C.
y Includes chronic lymphocytic leukemia/lymphoma, multiple myeloma, lymphomas not high grade.
z Includes acute myeloid leukemia, myelodysplastic syndrome, chronic myeloid leukemia (blast crisis, accelerated phase), myeloﬁbrosis, myeloproliferative
disorders.
x Includes acute lymphoblastic leukemia, high-grade lymphomas (Hodgkin lymphoma, diffuse large B cell lymphoma, transformed non-Hodgkin lymphoma).
M. Bar et al. / Biol Blood Marrow Transplant 19 (2013) 949e957950the discretion of the attending physician. Treatment with tyrosine kinase
inhibitor or interferon was generally discontinued before DLI. Patients were
eligible to receive DLI if they were not receiving systemic treatment forGVHD, had no evidence of active GVHD at the time of DLI, and had evidence
of donor chimerism. No immunosuppressive agents were given after DLI to
prevent GVHD. Among 128 patients with available information regarding
Figure 1. Outcome after donor lymphocyte infusion (DLI) according to initial
DLI cell dose. (A) Shows cumulative incidence of graft-versus-host disease
after DLI according to initial CD3þ cell dose. Twelve-month cumulative inci-
dence of GVHD for initial DLI cell dose group A (1  107 CD3þ cell/kg) was
21%, compared with 45% (P ¼ .01) for initial cell dose group B (>1  107 to
<10  107 CD3þ cell/kg) and 55% (P < .0001) for initial cell dose group C
(10  107 CD3þ cell/kg). (B) Shows overall survival after DLI according to
initial CD3þ cell dose. Three-year overall survival rates were 47% for cell
dose group A, 45% (P ¼ .16) for cell dose group B, and 32% for cell dose group C
(P ¼ .01).
M. Bar et al. / Biol Blood Marrow Transplant 19 (2013) 949e957 951the DLI product, 32 patients received a granulocyte-colony stimulating
factor (G-CSF) mobilized product for DLI. Twelve patients received IL-2 after
DLI as part of a prospective clinical trial, as previously described [17].
GVHD Deﬁnition
DLI-related GVHD was deﬁned as any acute GVHD [18] or chronic GVHD
(NIH criteria or historical criteria) [19,20] after DLI that required systemic
treatment. As clinically acute and chronic GVHD occurring after DLI have
overlapping onset times [21,22], for the purpose of evaluating the incidence
of GVHD after DLI, we deﬁned DLI-related GVHD as any GVHD after DLI
(acute or chronic) that required systemic treatment. Serious GVHD after DLI
was evaluated according to previously reported criteria [23].
Statistical Methods
Overall survival after DLI was estimated by the Kaplan-Meier method.
Cumulative incidence of relapse and GVHD after DLI were estimated by
standard methods, treating death as a competing risk. Cox regression was
used to evaluate risk factors for GVHD, OS, and relapse and disease
progression after DLI. Risk factors evaluated in univariate analysis for each of
the outcomes (GVHD, OS, and relapse or disease progression after DLI)
included initial DLI CD3þ cell dose, patient age at DLI, donor-recipient
gender, diagnosis at time of DLI, disease status at time of DLI, donor
origin, donor-recipient HLA match, graft stem cell source, conditioning
intensity, acute and chronic GVHD before DLI, interval between HCT to DLI,
cytoreductive treatment before DLI, donor blood CD3 and whole
marrow chimerism at the time of DLI, lymphocyte count at the time of DLI,
use of G-CSF-mobilized product for DLI, use of IL-2 after DLI, and year of DLI.
Multivariate models included all factors signiﬁcant at the .05 level in
univariate analysis for each outcome, as well as age and the factors most
signiﬁcantly disparate among the cell dose groups (donor origin, condi-
tioning intensity, and year of DLI). In analyzing the impact of subsequent DLI
on overall survival, the second DLI was treated as a time-dependent co-
variate in a Cox regression model. Comparisons of CD3þ cell dose between
the initial and second DLI was by paired t-test.
RESULTS
Patient Characteristics
A total of 225 patients underwent treatment with DLI for
persistent or relapse hematological malignancies after HCT
including CML (n ¼ 56), acute myeloid leukemia (AML)
(n ¼ 71), MDS (n ¼ 22), acute lymphoblastic leukemia (ALL)
(n ¼ 21), MM (n ¼ 23), lymphoma (n ¼ 21), chronic
lymphocytic leukemia (CLL)/lymphoma (n ¼ 8), myeloﬁ-
brosis (n ¼ 2), and myeloproliferative disorder (n ¼ 1).
Patients were classiﬁed into one of the following risk cate-
gories: (1) high-risk myeloid malignancies group that
included patients with AML, MDS, CML (blast crisis [BC],
accelerated phase [AP]), myeloﬁbrosis, and myeloprolifera-
tive disorder, (n ¼ 111); (2) high-risk lymphoid malignancies
group that included patients with ALL and high-grade
lymphomas (Hodgkin lymphoma, diffuse large B cell
lymphoma, transformed non-Hodgkin lymphoma), (n ¼ 37);
(3) low-risk lymphoid malignancies group that included
patients with CLL, MM, other lymphomas, (n ¼ 36); and (4)
those with CML-chronic phase (CP) (n ¼ 41).
The median age of the 225 patient cohort was 46 years
(range, 3 to 74), and 59% (n ¼ 132) were male. Patients
received transplantations from HLA-matched related (n ¼
171) or unrelated (n¼ 41) donors. Thirteen patients had HLA-
mismatched donors, and 58 patients (26%) received reduced-
intensity conditioning regimens before HCT. The median
time interval from HCT to relapse was 11.3 months (range, 1
to 180); from HCT to DLI, 15.5 months (range, 21.1 to 215).
One hundred forty-four patients (64%) received cytoreduc-
tive therapy before DLI, and 55 patients (24%) had achieved
complete remission at the time of DLI. The initial DLI CD3þ
cell dose per kilogramwas 1 107 in 84 patients (group A),
>1.0 to <10  107 in 58 patients (group B), and 10  107 in
66 patients (group C). The remaining 17 patients received an
unknown initial dose. Median follow-up after DLI was 78months (range, .1 to 197). Characteristics of the cohort
according to the initial DLI CD3þ cell dose administered are
shown in Table 1.GVHD after DLI
Of the 225 treated patients, 86 (39%) developed GVHD
that required systemic therapy after DLI, and 29 of 86 cases
had serious GVHD as previously deﬁned [23]. The median
interval from DLI to GVHD that required systemic treatment
was 39 days (range, 6 to 1029). The incidence rates of GVHD
at 12 months after DLI according to initial cell dose were 21%,
45%, and 55% for groups A, B, and C, respectively (Figure 1A).
Results of univariate and multivariate analysis of risk
factors for the development of GVHD after DLI are shown in
Table 2. In the multivariate analysis, 2 factors showed
a statistically signiﬁcant association with increased risk of
GVHD after DLI: (1) initial DLI CD3þ cell dose 10  107/kg
(hazard ratio [HR], 2.4; 95% CI, 1.1 to 5.4; P ¼ .03), and (2)
short interval between transplantation to DLI of 1 year or less
(HR, 2.95; 95% CI, 1.7 to 5.2; P¼ .0002) (Table 2). In univariate
analysis, higher initial CD3þ cell dose was associated with an
increased risk for serious GVHD after DLI for group B (HR,
Table 2
Risk Factors Analysis for GVHD after DLI
Univariate Multivariate (n ¼ 194)
HR (95% CI) P Value HR (95% CI) P Value
CD3þ cell dose
107 cells/kg 1.0 1.0
>107 to <108 cells/kg 2.74 (1.5-5.0) .001 1.82 (.9-3.7) .10
108 cells/kg 3.87 (2.2-6.9) <.0001 2.40 (1.1-5.4) .03
Patient age at DLI
0-29 yr 1.0 1.0
30-44 yr 1.06 (.6-2.0) .86 .82 (.4-1.8) .62
45-59 yr 1.26 (.7-2.3) .46 1.35 (.6-2.8) .42
60-74 yr .45 (.2-1.1) .09 .55 (.2-1.8) .32
Donor-recipient gender
Other 1.0
Female to male 1.26 (.8-2.1) .37
Disease diagnosis/risk at time of DLI
CML-chronic phase 1.0 1.0
Low-risk lymphoid malignancies* .94 (.4-2.3) .89 1.04 (.3-3.8) .95
High-risk myeloid malignanciesy 2.53 (1.3-4.8) .005 1.72 (.6-4.8) .30
High-risk lymphoid malignanciesz 1.65 (.7-3.7) .23 1.41 (.4-4.7) .58
Disease status at time of DLI
Complete remission 1.0 1.0
Not in complete remission .61 (.4-1.0) .03 .99 (.5-1.8) .97
Donor origin
Related 1.0 1.0
Unrelated .76 (.5-1.3) .29 .99 (.5-2.0) .97
Donor-recipient HLA match
Matched 1.0
Mismatched 1.10 (.4-2.7) .84
Graft stem cell source
Bone marrow 1.0
Mobilized blood 1.04 (.7-1.6) .86
Conditioning intensity
Myeloablative 1.0 1.0
Nonmyeloablative .57 (.3-1.0) .04 .71 (.3-1.6) .42
Prior acute GVHD (n ¼ 218)
0-I 1.0
II-IV 1.32 (.8-2.1) .23
Prior chronic GVHD
No 1.0
Yes 1.24 (.8-1.9) .34
Time from HCT to DLI
>1 yr 1.0 1.0
1 yr 2.57 (1.7-3.9) <.0001 2.95 (1.7-5.2) .0002
Cytoreduction before DLI
No 1.0 1.0
Yes 1.88 (1.2-3.1) .01 1.32 (.6-2.9) .48
Donor CD3 chimerism at time of DLI
>95% 1.0
95% 1.87 (.8-4.1) .12
Donor BM chimerism at time of DLI
>95% 1.0
95% 1.26 (.7-2.3) .46
Lymphocyte count at time of DLI
103/mL 1.0 1.0
<103/mL 2.13 (1.4-3.3) .0008 1.41 (.8-2.3) .19
G-CSF mobilized product for DLI
No 1.0
Yes .95 (.5-1.8) .87
IL-2 after DLI
No 1.0
Yes 1.22 (.6-2.6) .62
Year of DLI
1992-1996 1.0 1.0
1997-2001 .77 (.4-1.3) .34 .93 (.5-1.8) .83
2002-2006 .57 (.3-1.0) .05 .67 (.3-1.3) .25
2007-2011 .21 (.1-.6) .002 .33 (.1-1.1) .07
DLI indicates donor lymphocyte infusion; HR, hazard ratio; CML, chronic myeloid leukemia; GVHD, grant-versus-host disease; HCT, hematopoietic cell trans-
plantation; BM, bone marrow; G-CSF, granulocyte-colony stimulating factor.
* Includes chronic lymphocytic leukemia/lymphoma, multiple myeloma, lymphomas not high grade.
y Includes acute myeloid leukemia, myelodysplastic syndrome, chronic myeloid leukemia (blast crisis, accelerated phase), myeloﬁbrosis, myeloproliferative
disorders.
z Includes acute lymphoblastic leukemia, high-grade lymphomas (Hodgkin lymphoma, diffuse large B cell lymphoma, transformed non-Hodgkin lymphoma).
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Figure 2. Overall survival after donor lymphocyte infusion (DLI) according to
initial CD3þ cell dose and disease risk category. (A) Shows the overall survival
for the low-risk category. One- and 3-year overall survival were 94% and 73%
for cell dose A, 67% and 53% for cell dose B, and 60% and 55% for cell dose C
(P ¼ .07). Low-risk category included chronic myeloid leukemia-chronic phase
and chronic lymphocytic leukemia, multiple myeloma, and low-risk
lymphomas. (B) Shows the overall survival for the high-risk category. One-
and 3-year overall survival were 47% and 27% for cell dose group A, 60% and
42% for cell dose group B, and 41% and 22% for cell dose group C (P ¼ .35).
High-risk category included high-risk myeloid malignancies (acute myeloid
leukemia, myelodysplastic syndrome, chronic myeloid leukemia [blast crisis,
accelerated phase], myeloﬁbrosis, myeloproliferative disorders, and high-risk
lymphoid malignancies [acute lymphoblastic leukemia, high-grade
lymphomas [Hodgkin lymphoma, diffuse large B cell lymphoma, trans-
formed non-Hodgkin lymphoma]).
M. Bar et al. / Biol Blood Marrow Transplant 19 (2013) 949e957 9534.34; 95% CI, 1.4 to 13.6; P ¼ .01) and for group C (HR, 4.80;
95% CI, 1.6 to 14.7; P¼ .006) compared to group A. Because of
the small number of patients experiencing serious GVHD,
multivariate analysis was not performed. Although DLI given
in more recent years was associated with a decreased risk of
GVHD in the univariate analysis, this factor did not reach
statistical signiﬁcance in the multivariate analysis. A history
of acute or chronic GVHD before DLI or donor type was not
statistically signiﬁcantly associated with increased risk of
GVHD after DLI (Table 2).
Overall Survival after DLI
The overall survival rates at 3 years according to initial DLI
cell dose were 47%, 45%, and 32% for groups A, B, and C,
respectively (Figure 1B). At the time of analysis, 71 patients
(31%) were alive after DLI. Survivors were 28 of 41 patients
(68%) treated for CML-CP, 3 of 15 patients (20%) treated for
CML-AP/BC, 15 of 71 patients (21%) for AML, 4 of 21 patients
(19%) for ALL, 1 of 22 patients (4%) for MDS, 7 of 23 patients
(30%) for MM, 2 of 8 patients (25%) for CLL, and 8 of 21
patients (38%) treated for lymphomas, 2 of 2 patients with
myeloﬁbrosis, and 1 patientwithmyeloproliferative disorder.
As demonstrated in Table 1, we found no statistically
signiﬁcant imbalance in the distribution of diagnosis risk
groups between the 3 initial DLI CD3þ cell dose groups (P ¼
.36). Because of the small number of patients in each of the
initial DLI cell dose groups in the different diagnostic risk
groups (ie, CML-CP, low-risk lymphoid, low-riskmyeloid, and
high-risk lymphoid malignancies), these 4 diagnostic risk
groups were combined into 2 risk categories for the analysis
of OS according to the initial DLI CD3þ cell dose, as follows:
(1) low-risk disease, including CML-CP, CLL, MM, low-grade
lymphomas and (2) high-risk disease, including myeloid
malignancies (AML, MDS, CML-AP/BC), myeloﬁbrosis,
myeloproliferative disorder, and high-risk lymphoid malig-
nancies (ALL, high-grade lymphomas [Hodgkin lymphoma,
diffuse large B cell lymphoma, transformed non-Hodgkin
lymphoma]). Figure 2 shows the univariate analysis of OS
after DLI according to the initial CD3þ cell dose and the 2
diagnosis risk categories. The 3-year OS for the low-risk
category was 73% for group A, 53% for group B, and 55% for
group C (P ¼ .07) (Figure 2A). The 3-year OS for the high-risk
category was 27% for group A, 42% for group B, and 22% for
group C, but the difference in OS between the 3 cell doses
was not statistically signiﬁcant (P ¼ .35) (Figure 2B).
Univariate analysis of OS according to the initial CD3þ cell
dose for speciﬁc diagnosis such as CML and other disease
categories is shown in Supplemental Figure 1. For patients
treated with DLI for relapsed CML, 3-year OS according to the
initial DLI cell dose was 81% for group A, 46% for group B, and
50% for group C, but these differences did not reach statistical
signiﬁcance (P ¼ .07) (Supplemental Figure 1A). For patients
given DLI for relapsed lymphoma, CLL, and MM, the 1- and
3-year OS were 85% and 43%, respectively, for patients given
cell dose A; 91% and 64%, respectively for patients treated
with cell dose B; and 46% and 31%, respectively, for cell dose
C. These differences were not statistically signiﬁcant (P¼ .25)
(Supplemental Figure 1B). No association between initial DLI
CD3þ cell dose and OS was noted for patients treated for
relapsed AML orMDSwith 3-year OS of 32%, 40%, and 28% for
initial DLI CD3þ cell doses A, B and C, respectively (P ¼ .99)
(Supplemental Figure 1C).
Results of multivariate analysis for risk factors for
mortality after DLI are presented in Table 3. Three factors
were statistically signiﬁcantly associated with an increasedrisk of mortality after DLI: (1) DLI within 1 year after HCT
(HR, 2.66; 95% CI, 1.7 to 4.2; P < .0001); (2) age 60 or older
(HR, 2.69; 95% CI, 1.1 to 6.3; P ¼ .02); and (3) high-risk
lymphoid malignancies (HR, 2.62; 95% CI, 1.0 to 6.8; P ¼
.05). As shown in Table 2, a trend for an association between
high-risk myeloid malignancies and an increased mortality
risk was noted (P¼ .06). More recent DLI was associated with
decreased risk formortality, with an HR of .27 (95% CI, .1 to .6;
P ¼ .002) for patients treated with DLI between 2007 to 2011
comparedwith patients treated between 1992 to 1996. Initial
DLI cell dose did not affect mortality either for the entire
cohort (Table 3) or for the cohort of patients with diseases
other than CML-CP (group B: HR, .88; P ¼ .61; group C: HR,
1.22; P ¼ .51).
Of the 225 patients, 46 received 2 DLIs, 13 patients
received 3 DLIs, and 1 patient received 4 DLIs. A time-
dependent Cox regression analysis showed no signiﬁcant
effect of subsequent DLIs on OS (HR, .95; 95% CI, .6 to 1.4,
P ¼ .82).
Table 3
Risk Factor Analysis for Overall Mortality after DLI
Univariate Multivariate (n ¼ 181)
HR (95% CI) P Value HR (95% CI) P Value
CD3þ cell dose
107 cells/kg 1.0 1.0
>107 to <108 cells/kg 1.35 (.9-2.0) .16 .98 (.6-1.7) .93
108 cells/kg 1.64 (1.1-2.4) .01 1.25 (.7-2.3) .48
Patient age at DLI
0-29 yr 1.0 1.0
30-44 yr .99 (.6-1.6) .95 1.02 (.6-1.9) .95
45-59 yr 1.02 (.6-1.6) .94 1.44 (.8-2.7) .25
60-74 yr 1.42 (.8-2.4) .20 2.69 (1.1-6.3) .02
Donor-recipient gender
Other 1.0
Female to male 1.19 (.8-1.7) .38
Disease diagnosis/risk at time of DLI
CML-chronic phase 1.0 1.0
Low-risk lymphoid malignancies* 2.93 (1.5-5.8) .002 1.47 (.5-4.2) .48
High-risk myeloid malignanciesy 5.05 (2.8-9.1) <.0001 2.29 (1.0-5.4) .06
High-risk lymphoid malignanciesz 4.64 (2.4-9.0) <.0001 2.62 (1.0-6.8) .05
Disease status at time of DLI
Complete remission 1.0
Not in complete remission 1.18 (.8-1.7) .39
Donor origin
Related 1.0 1.0
Unrelated .86 (.6-1.3) .44 1.05 (.6-1.8) .87
Donor-recipient HLA match
Matched 1.0
Mismatched 1.14 (.6-2.2) .70
Graft stem cell source
Bone marrow 1.0 1.0
Mobilized blood 1.72 (1.2-2.4) .002 1.42 (.8-2.5) .22
Conditioning intensity
Myeloablative 1.0 1.0
Nonmyeloablative 1.24 (.9-1.8) .24 0.75 (.4-1.6) .46
Prior acute GVHD (n ¼ 218)
0-I 1.0
II-IV 1.07 (.8-1.5) .68
Prior chronic GVHD
No 1.0
Yes .98 (.7-1.4) .89
Time from HCT to DLI
>1 yr 1.0 1.0
1 yr 3.04 (2.2-4.2) <.0001 2.66 (1.7-4.2) <.0001
Cytoreduction before DLI
No 1.0 1.0
Yes 2.35 (1.6-3.4) <.0001 1.37 (.7-2.5) .31
Donor CD3 chimerism at time of DLI
>95% 1.0
95% 1.39 (.8-2.4) .25
Donor BM chimerism at time of DLI
>95% 1.0
95% 2.08 (1.3-3.3) .003
Lymphocyte count at time of DLI
103/mL 1.0 1.0
<103/mL 1.72 (1.2-2.4) .001 1.16 (.8-1.8) .50
G-CSF mobilized product for DLI
No 1.0
Yes 1.06 (.7-1.7) .81
IL-2 after DLI
No 1.0
Yes 1.41 (.8-2.5) .23
Year of DLI
1992-1996 1.0 1.0
1997-2001 .89 (.6-1.4) .59 .65 (.4-1.1) .10
2002-2006 .79 (.5-1.2) .30 .46 (.2-.9) .02
2007-2011 .58 (.3-1.1) .09 .27 (.1-.6) .002
DLI indicates donor lymphocyte infusion; HR, hazard ratio; CML, chronic myeloid leukemia; GVHD, grant-versus-host disease; HCT, hematopoietic cell trans-
plantation; BM, bone marrow; G-CSF, granulocyte-colony stimulating factor.
* Includes chronic lymphocytic leukemia/lymphoma, multiple myeloma, lymphomas not high grade.
y Includes acute myeloid leukemia, myelodysplastic syndrome, chronic myeloid leukemia (blast crisis, accelerated phase), myeloﬁbrosis, myeloproliferative
disorders.
z Includes acute lymphoblastic leukemia, high-grade lymphomas (Hodgkin lymphoma, diffuse large B cell lymphoma, transformed non-Hodgkin lymphoma).
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Table 4
Cause of Death According to Initial DLI CD3 Cell per Kilogram Dose Groups
Group A
(n ¼ 49)
Group B
(n ¼ 41)
Group C
(n ¼ 55)
GVHD 4 (8%) 3 (7%) 5 (9%)
Relapse or progressive disease 44 (90%) 30 (73%) 37 (67%)
Relapse or progressive disease
and GVHD
0 3 (7%) 4 (7%)
Other cause death 0 3 (7%) 4 (7%)
Unknown cause of death 1 (2%) 2 (5%) 5 (9%)
GVHD indicates graft-versus-host disease.
Data are presented as n (%) unless otherwise indicated. P ¼ .32 (excluding
unknown causes)
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A total of 154 patients have died. Deaths occurred in 49 of
84 patients (58%) in cell group A, in 41 of 58 patients (71%) in
cell dose group B, and in 55 of 66 patients (83%) in cell group
C. The most common cause of death after DLI was progres-
sive disease or relapse of malignancy in all 3 cell dose groups:
90% of deaths in group A, 73% of deaths in group B, and 67%
of deaths in group C. GVHDwas the primary cause of death in
4 patients (8%) in group A, 3 patients (7%) in group B, and 5
patients (9%) in group C. Table 4 summarizes the cause of
death according to the initial DLI cell dose groups.
Relapse and Disease Progression after DLI
Among the 225 patients, 166 (74%) had relapse and/or
progressive disease after DLI. Results of univariate and
multivariate analysis for relapse and/or progressive disease
after DLI are shown in Supplemental Table 1. Three factors
statistically signiﬁcantly affected the risk of relapse or
disease progression after DLI in the multivariate analysis: (1)
interval of 1 year or less from HCT to DLI (HR, 1.92; 95% CI, 1.3
to 2.9; P ¼ .002); (2) age of 60 and older (HR, 2.33; 95% CI, 1.1
to 5.1; P ¼ .03); and (3) initial CD3þ cell dose of >1 107 to
<10 107/kg compared with lower cell dose (HR, .54; 95% CI,
.3 to .9; P ¼ .01). Initial CD3þ cell dose of 10  107/kg was
not associated with decreased relapse rate. Analysis for risk
of relapse according to the initial DLI CD3þ cell dose among
patients with diseases other than CML-CP showed similar
results. The intermediate cell dose was associated with
a decreased relapse rate (HR, .57; 95% CI, .4 to .9; P ¼ .02), but
the highest cell dose was not.
Aplasia after DLI
Aplasia after DLI was evaluated in 154 patients who
participated in prospective DLI studies for relapsed hema-
tological malignancies after HCT. Fifteen of 154 (9.7%)
patients developed aplasia after DLI. Five of 15 patients
received an initial DLI dose of 10  107 CD3þ/kg, 2 patients
received a dose of 9  107 CD3þ/kg, 1 patient received a dose
of 2.5  107 CD3þ/kg, and the rest of the patients received
a dose of 1  107 CD3þ/kg.
DISCUSSION
DLI is an attractive salvage treatment option for patients
with persistent or relapsed hematological malignancies after
high- or reduced-intensity HCT [7-11]. Previous studies have
suggestedoptimal initial totalnucleatedcells and lymphocyte
doses of DLI associatedwith a low risk of GVHD andmortality
and yet maintenance of the desirable graft-versus-
malignancy effect for treatment of relapsed CML after allo-
geneicHCT [14-16]. Limiteddata areavailable on the impactof
DLI CD3þ cell dose onGVHDandmortalityafterDLI inpatients
treated for other hematological malignancies, however, andthe appropriate initial cell dose of DLI for treatment of
recurrent non-CML hematological malignancies after HCT
remained unsettled. Thus, the primary objective of our study
was todetermine theeffectof the initialDLI cell dose onGVHD
and OS after DLI in patients treated for any hematological
malignancies that relapsed after allogeneic HCT.
DLI contains a variety of cell types, and the response to
DLI could be mediated by several mechanisms. T lympho-
cytes have signiﬁcant effects on both graft-versus-leukemia
and GVHD because of their longevity after transfusion
in vivo and their ability to target minor histocompatibility
antigens shared between leukemic and normal host tissue as
well as antigens unique to leukemia cells [24-26]. Therefore,
we focused our analysis on the effect of the initial CD3þ T cell
dose on GVHD and survival after DLI. This retrospective
analysis of 225 patients conﬁrms that adoptive immuno-
therapy with donor lymphocytes may be an effective treat-
ment for patients with hematological malignancies who
experience relapse after allogeneic HCT, and the results
suggest that the initial CD3þ cell dose may inﬂuence the
outcome independently of other relevant factors.
Our multivariate analysis suggests that the risk for
developing GVHD after DLI signiﬁcantly increases with CD3þ
cell dose 10  107/kg, regardless of diagnosis, pre-DLI acute
or chronic GVHD, or interval between HCT and DLI. GVHD,
a pathological process initiated by the activation of donor T
cell after adoptive transfer into the allogeneic recipient [27],
has been a major direct complication after DLI [7,17,24,28-
34]. Earlier reports demonstrated that the dose of alloge-
neic total nucleated cells and lymphocytes infused for DLI is
a risk factor of GVHD after DLI in patients with relapsed CML
[14,21,30]. Chalendon et al. showed that>1107 CD3þ cells/
kg was correlated with a higher frequency of GVHD after DLI
in patients with relapsed CML after HCT [21]. In our study,
initial DLI CD3þ cell dose of 10  107/kg was associated
with a 2.4-fold increase in the risk of GVHD after DLI
compared with cell doses 1.0  107 in patients treated for
any hematological malignancy that relapsed or progressed
after allogeneic HCT after either high-intensity or reduced-
intensity conditioning. Initial DLI CD3þ cell dose of >1.0 
107 to<10 107/kgwas not associatedwith an increased risk
for GVHD compared to a lower cell dose.
We then sought to determine the effect of the initial CD3þ
cell dose on OS after DLI. Earlier studies evaluated the effect
of DLI mononuclear cells or T cell dose for the treatment of
CML [14,15]. Guglielmi et al. demonstrated that for the
treatment of relapsed CML, an initial DLI cell dose of .20 
108 mononuclear cells/kg was associated with less GVHD and
better survival than higher mononuclear cell doses [14].
Similar to the ﬁndings by Guglielmi et al., we demonstrated
better OS for patients with relapsed CML who were treated
with lower initial DLI CD3þ cell dose. Although our associa-
tion did not reach statistical signiﬁcance, likely because of
the small cohort, our and earlier results demonstrate that for
patients with CML, initial CD3þ cell dose of 1  107 or lower
has survival advantage as compared to higher CD3þ cell dose.
In contrast to the association between initial DLI CD3þ cell
dose and OS in CML, we did not demonstrate such an asso-
ciation for patients with AML or MDS. Earlier analyses to
evaluate the correlation between cell dose and response rate
in AML showed that increasing the cell dose beyond 1.5108
T cell/kg did not add to the response rate [35]. A study by
Choi et al., however, appeared to show a better response rate
with a higher dose of T cells [36]. In our study, we demon-
strated 3-year overall survival of 32%, 40%, and 28% for
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CD3þ cells/kg, 1.1 to 9.9  107 CD3þ cells/kg, and 10  107
CD3þ cells/kg, respectively (P ¼ .99). Although these results
do not demonstrate correlation between initial DLI CD3þ cell
dose and OS, they do show that initial DLI CD3þ cell
dose 10  107/kg does not provide survival beneﬁt.
Therefore, considering that an initial DLI cell dose of 10 
107 CD3þ cells/kg is associated with an increased risk of
GVHD after DLI, our results suggest that initial CD3þ cell
doses 10  107/kg should be avoided. Although we found
no statically signiﬁcant difference between initial cell dose
groups and OS, patients in the low-risk disease category
might achieve better survival with a lower DLI cell dose
(Figure 2A). Our evaluation of the relationship between CD3þ
cell dose and OS for lymphoma, CLL, and MM showed an
association between the initial DLI CD3þ cell dose and OS;
however, this association did not reach statistical signiﬁ-
cance (Supplemental Figure 1B). The number of ALL patients
in our cohort was too small to derive signiﬁcant conclusions.
Relapse or progressive disease was the main cause of
death after DLI at all 3 cell dose groups, with no statistically
signiﬁcant decrease in the proportion of patients who died
because of relapse among patients who were treated with
higher CD3þ cell doses.
We then evaluated the association between initial DLI cell
dose and relapse or disease progression after DLI. Our data
demonstrate a decreased risk of relapse and/or disease
progression with initial DLI CD3þ dose of >1  107 to <10 
107 but not with higher cell dose. The results were not
different when CML-CP patients were excluded from the
analysis. Similar observations have been made previously in
ALL patients treated with DLI [35]. Although no conclusive
statement can be made because of the small numbers, the
lower response rates with higher CD3þ cell dose could reﬂect
higher numbers of infused T regulatory cells, which might
dampen the graft-versus-tumor effect.
This study has several limitations. The data were mostly
collected retrospectively, the patient population is heteroge-
neous, patients were treated according to a variety of proto-
cols with different treatment strategies, and methods and
timing of follow-up were not standardized. Additionally,
better supportive care has improved the survival of patients
who were treated in more recent years compared with
patients who were treated earlier. Despite those limitations,
webelieve that this studygives a reliable estimateof the effect
of initial CD3þ cell dose on GVHD and survival after DLI for
treatment of relapsed hematological malignancies after HCT.
Our results demonstrate that an initial DLI CD3þ cell dose
per kilogram 10  107 is associated with increased risks of
GVHD after DLI, without improving survival. These ﬁndings
are clinically relevant, because they support a recommenda-
tion to infuse less than 10 107 CD3þ cell/kg as the initial cell
dose of DLI for treatment of recurrent hematological malig-
nancy, including non-CML after allogeneic HCT.
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